Indonesia is one of Southeast Asia’s most attractive healthcare markets — but it is also one of the most complex to navigate. Many international brands enter with optimism and exit with costly lessons. Here are five mistakes we see most often, and how to avoid them.
1. Underestimating the Regulatory Timeline
Medical device registration in Indonesia is not a quick process. Brands that assume a 3-month turnaround often find themselves waiting 12 months or more. Documentation gaps, incorrect product classification, and missing local representative appointments are the most common causes of delay.
2. Choosing the Wrong Local Partner
A distributor with a large network is not automatically the right fit. The right partner understands your product category, has CDAKB compliance in place, and aligns with your growth objectives. Taking time to evaluate partners properly saves significant trouble down the road.
3. Skipping Market Validation
Assuming that a product that works in other Asian markets will automatically work in Indonesia is a risky move. Healthcare procurement patterns, hospital decision-making, and end-user needs in Indonesia have their own dynamics that require proper validation.
4. Ignoring Post-Market Requirements
Getting the Izin Edar is just the beginning. Post-market surveillance, periodic reporting, and maintaining CDAKB compliance are ongoing requirements. Brands that treat registration as a one-time task often face compliance issues later.
5. Moving Too Fast Without Local Insight
Speed is important, but moving fast without understanding the local healthcare ecosystem — procurement channels, government hospital vs. private clinic dynamics, regional distribution — leads to wasted resources. A structured, insight-driven approach always outperforms a rushed one.
Avoiding these mistakes starts with the right preparation and the right local partner. If you are planning your Indonesia market entry, we are happy to help you think it through.
Tinggalkan Balasan